

### This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Drug platforms</b>			
Disulfide bond-linked nanoparticle-antigen conjugates to increase pulmonary cytotoxic T cell responses	Disulfide-linked nanoparticle-antigen conjugates could be useful for creating vaccines that elicit pulmonary cytotoxic T cell responses. In mice, intranasal delivery of a model antigen linked to a nanoparticle increased Cd8 <sup>+</sup> T cell responses and improved protection against an engineered influenza strain compared with unconjugated antigen. Next steps include testing the vaccine in additional pulmonary indications, including lung cancer and tuberculosis.  <i>SciBX</i> (42); doi:10.1038/scibx.2011.1193 Published online Oct. 27, 2011	Patent application filed; licensed to the authors, who are seeking development partners	Nembrini, C. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Oct. 3, 2011; doi:10.1073/pnas.1104264108 <b>Contact:</b> Jeffrey A. Hubbell, Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland e-mail: <a href="mailto:jeffrey.hubbell@epfl.ch">jeffrey.hubbell@epfl.ch</a> <b>Contact:</b> Melody A. Swartz, same affiliation as above e-mail: <a href="mailto:melody.swartz@epfl.ch">melody.swartz@epfl.ch</a>